36 Krypton learned that Ronovo, a research and development company for endoscopic surgical robots, has recently completed tens of millions of dollars in Pre-B round financing, led by LRI Jiangyuan Investment. All old shareholders include Lilly Asia Fund, Vivo Capital, Matrix Partners, and GGV Capital participated in the follow-up investment. Yikai Capital acted as the exclusive financial advisor of Ruilong Nuofu in this round of financing.
This round of financing will be used to accelerate the multi-specialty clinical trials of Ruilong Nuofu modular surgical robot, strengthen the company’s platform product research and development and clinical capacity building, and increase the company’s talent construction.
In medical scenarios, doctors, enterprises and many other parties hope to promote advanced diagnosis and treatment technologies to more hospitals. In current clinical applications, integrated surgical robots are relatively common, but the admission price of imported endoscopic surgery robots is tens of millions of RMB, and the price of robot-assisted endoscopic surgery is 40,000-50,000 RMB higher than that of ordinary endoscopic surgery, and more Pay for the patient. In addition, for surgeons, at least a learning cycle of more than 30 operations is required to master the corresponding techniques.
In order to reduce costs and achieve specialist coverage, Nuofu founder Ma Changzheng and co-founder Mao Ying led the team to develop a modular and dexterous surgical robot. According to the clinical needs of the hospital, the robot system of Ruilong Nuofu can set up different product combinations, which are composed of the main console, different numbers of operating arm trolleys, 3D laparoscope and performing surgical instruments.
Source: Ruilong Nuofu
“There are four surgical arms on the one-piece surgical robot similar to Da Vinci, but in actual clinical applications in the Chinese market, these four surgical arms are used in less than 10% of the application scenarios, and only three are used in more than 90% of the cases,” said Ma Changzheng Introduced.
The surgical robot developed by Ruilong Nuofu adopts a modular design, which separates the operating arm separately, so that the hospital can choose the number of trolleys according to actual needs; the modular trolley can be flexibly positioned according to the surgical method, and can also be used between different operating rooms. It is convenient to move; it occupies a small area, which can better adapt to the existing operating room environment of Chinese secondary and tertiary hospitals, so as to reduce the cost of admission and patient use.
“The differentiated clinical capabilities and economical suitability of the modular laparoscopic surgical robot system will greatly accelerate the popularization of robotic minimally invasive surgery in general surgery, gynecology, thoracic surgery, urology and other specialties.” Ma Changzheng said, for According to the actual needs of nearly 10 million minimally invasive surgery patients, 120,000 laparoscopic doctors, and over 10,000 secondary and tertiary hospitals every year in China, Ruilong Nuofu has completed innovative modular and smart product design and has complete autonomy intellectual property.
The surgical robot is an extension of the doctor’s hands. When considering extending the doctor’s hands, how can the doctor’s vision be enhanced so that the doctor can see more clearly on the basis of allowing the doctor to operate accurately and flexibly?
The high-definition 3D laparoscopy system of Ruilong Nuofu integrates ICG fluorescence imaging function, and combines 3D reconstruction and regional blood flow fluorescence visualization imaging technology to perform laparoscopic robotic surgery (RAS). 3D reconstruction technology is used before operation to see pathological information such as patient-specific tissue structure and lesion location; intraoperative ICG fluorescence imaging technology is used to evaluate blood perfusion, tissue identification, and tumor resection margin analysis to show the surgical effect and optimize the operation Strategy.
When talking about the functional imaging system, Mao Ying, co-founder of the company, said: “Functional imaging has a very clear clinical value. During the operation, the human tissue structure can be presented to the doctor through imaging. The doctor can do it in advance or in real time. Obtaining this information will make the operation safer and more precise, and finally bring better curative effect to patients.” According to him, functional imaging systems and surgical robots have the same strategic height, which is the direction that the company will focus on development .
In terms of team, after 3 years of development, the current team size of Ruilong Nuofu exceeds 100 people, of which 19 are returnees with experience in robotics, 80% are R&D personnel, and more than 80% have a master’s degree or above. The founder of the company, Ma Changzheng, served as the former senior vice president of strategic development of Intuitive Surgery and the former global partner of Fosun Group; the co-founder Mao Ying was the head of robot control research and development of Auris Health (later acquired by Johnson & Johnson for US$5.6 billion), Dreamworld AR co-founder, has 14 years of research and development experience in the field of robotics.
At present, the endoscopic surgical robots that have been launched in China include Da Vinci Si/Xi, Weigao Miaoshou and Minimally Invasive Tumai, most of which are integrated; in terms of international experience, the CMR Versius surgical robot, which has been successfully commercialized and performed stably, uses the Modular design. In 2021, there will be about 9.5 million laparoscopic surgeries in China, mainly carried out in the four departments of gynecology, general surgery, thoracic surgery, and urology. Among them, the penetration rate of laparoscopic surgery robots ranks first in urology surgeries, and other There is still a lot of room for expansion of robotic surgery in departments.
Investor’s point of view
Zhang Jiang, founder and CEO of LRI Jiangyuan Investment, said: Ronovo is a leading company of modular surgical robots in China, and has an outstanding team with international vision, profound industrial background and efficient execution. Through a deep insight into market trends, the company has created core products that are close to the real clinical needs in China. We are very pleased to help Ronovo further promote product development and clinical application, and believe that the modular abdominal hand robot developed by the team can create differentiated commercial and clinical value, and continue to move towards the goal of internationalization.
media reports
Arterial.com Yiou Arterial.com 36Kr Investment Circle ChinaVenture
related events
- Nuofu completed tens of millions of US dollars Pre-B round of financing2022-12-21
- Applying digital surgical technology to minimally invasive surgery, “Ruilong Nuofu” completed hundreds of millions of yuan in Series A financing2021-04-23
This article is transferred from: https://readhub.cn/topic/8lUZNrwGnNu
This site is only for collection, and the copyright belongs to the original author.